IL139700A - Immunotherapeutic composition for the treatment of prostate cancer - Google Patents

Immunotherapeutic composition for the treatment of prostate cancer

Info

Publication number
IL139700A
IL139700A IL13970099A IL13970099A IL139700A IL 139700 A IL139700 A IL 139700A IL 13970099 A IL13970099 A IL 13970099A IL 13970099 A IL13970099 A IL 13970099A IL 139700 A IL139700 A IL 139700A
Authority
IL
Israel
Prior art keywords
treatment
prostate cancer
immunotherapeutic composition
prostate
immunotherapeutic
Prior art date
Application number
IL13970099A
Other languages
English (en)
Other versions
IL139700A0 (en
Original Assignee
Altarex Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altarex Medical Corp filed Critical Altarex Medical Corp
Publication of IL139700A0 publication Critical patent/IL139700A0/xx
Publication of IL139700A publication Critical patent/IL139700A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL13970099A 1998-06-15 1999-06-15 Immunotherapeutic composition for the treatment of prostate cancer IL139700A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8928198P 1998-06-15 1998-06-15
PCT/IB1999/001115 WO1999065523A1 (en) 1998-06-15 1999-06-15 Immunotherapeutic composition and method for the treatment of prostate cancer

Publications (2)

Publication Number Publication Date
IL139700A0 IL139700A0 (en) 2002-02-10
IL139700A true IL139700A (en) 2005-09-25

Family

ID=22216751

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13970099A IL139700A (en) 1998-06-15 1999-06-15 Immunotherapeutic composition for the treatment of prostate cancer

Country Status (9)

Country Link
US (3) US6881405B2 (de)
EP (1) EP1085905B1 (de)
JP (1) JP2002518347A (de)
AT (1) ATE480566T1 (de)
AU (1) AU768002B2 (de)
CA (1) CA2328504A1 (de)
DE (1) DE69942742D1 (de)
IL (1) IL139700A (de)
WO (1) WO1999065523A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
IL139700A (en) * 1998-06-15 2005-09-25 Altarex Medical Corp Immunotherapeutic composition for the treatment of prostate cancer
HU226150B1 (en) 1999-01-13 2008-05-28 Igeneon Krebs Immuntherapie Use of antibodies for anticancer vaccination
EP1294397A2 (de) * 2000-05-11 2003-03-26 Altarex Corp. Therapeutische methode und zusammensetzung die eine antigen-antikörper komplexbildung und dessen präsentation durch dendritische zellen verwenden
CA2481796A1 (en) * 2002-04-11 2003-10-23 Altarex Medical Corporation Binding agents and their use in targeting tumor cells
EP1578445A4 (de) * 2002-10-17 2007-04-04 Altarex Medical Corp Therapeutisches adjuvans
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
GB0329146D0 (en) * 2003-12-16 2004-01-21 Glaxosmithkline Biolog Sa Vaccine
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
US20080095790A1 (en) * 2006-10-24 2008-04-24 Perambakam Supriya M Methods of Treating Prostate Cancer
CN106310293A (zh) 2007-09-27 2017-01-11 免疫疫苗技术有限公司 在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
WO2009126817A2 (en) 2008-04-09 2009-10-15 Advanced Immune Therapeutics, Inc. Ige antibodies for the treatment of cancer
AU2009253780B2 (en) * 2008-06-05 2014-08-14 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
GB0811567D0 (en) * 2008-06-24 2008-07-30 Cytosystems Ltd Assay
PL3903829T3 (pl) 2009-02-13 2023-08-14 Immunomedics, Inc. Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo
EP2478110B1 (de) 2009-09-16 2016-01-06 Immunomedics, Inc. Klasse-i-anti-cea-antikörper und verwendungen davon
WO2011068845A1 (en) 2009-12-02 2011-06-09 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
WO2011073215A2 (en) * 2009-12-14 2011-06-23 Immatics Biotechnologies Gmbh Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
CA2831572C (en) 2011-05-02 2019-11-26 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
EP2763698B1 (de) 2011-10-06 2020-12-02 ImmunoVaccine Technologies Inc. Liposomzusammensetzungen mit einem adjuvans zur aktivierung oder steigerung der aktivität von tlr2 und verwendungen davon
EP2885002A4 (de) 2012-08-14 2016-04-20 Ibc Pharmaceuticals Inc Umleitung t-zell-bispezifischer antikörper zur behandlung von krankheiten
WO2017004144A1 (en) 2015-07-01 2017-01-05 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
AU2013360335B2 (en) 2012-12-13 2017-12-07 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
WO2015126548A1 (en) 2014-02-21 2015-08-27 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to trop-2 expressing cells
CN106029098A (zh) 2014-02-25 2016-10-12 免疫医疗公司 人源化rfb4抗cd22抗体
WO2015200260A1 (en) 2014-06-24 2015-12-30 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
EP3954373A1 (de) 2014-10-07 2022-02-16 Immunomedics, Inc. Neoadjuvante verwendung von antikörper-wirkstoff-konjugaten
CN107428837A (zh) 2015-04-22 2017-12-01 免疫医疗公司 循环trop‑2阳性癌细胞的分离、检测、诊断和/或鉴定
EP3313443B9 (de) 2015-06-25 2023-10-04 Immunomedics, Inc. Kombination von anti-hla-dr- oder anti-trop-2-antikörpern mit mikrotubuli-inhibitoren, parp-inhibitoren, bruton-kinase-inhibitoren oder phosphoinositol-3-kinase-inhibitoren zur signifikanten verbesserung des therapeutischen ergebnisses bei krebs
JPWO2022239720A1 (de) 2021-05-10 2022-11-17

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865689A (en) 1972-11-09 1975-02-11 Hoffmann La Roche Method of producing carcinoembryonic antigens
US4446122A (en) 1979-12-28 1984-05-01 Research Corporation Purified human prostate antigen
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US5053224A (en) 1983-11-07 1991-10-01 Hilary Koprowski Induction of antibody response to solid tumors with anti-idiotype antibodies
JPH01502978A (ja) 1985-07-05 1989-10-12 フレッド　ハッチンソン　カンサー　リサーチ　センター 免疫原性の低下及び免疫寛容の誘導のための方法
EP0234122A3 (de) 1986-02-21 1989-03-22 Oncogen Limited Partnership Tumortherapie mit biologisch aktiven Anti-Tumor-Antikörpern
NZ222509A (en) 1986-11-19 1993-03-26 Oncogen Hybridoma cell line producing antibodies binding to tumour-associated mucin antigen
US5059680A (en) 1986-11-24 1991-10-22 Centocor, Inc. Method of isolating ca 125 antigen
US5683674A (en) 1987-01-07 1997-11-04 Imperial Cancer Research Technology Ltd. Antibody against human mucin core protein and method of preparing and using same
US4859449A (en) 1987-09-14 1989-08-22 Center For Molecular Medicine And Immunology Modified antibodies for enhanced hepatocyte clearance
GB8728856D0 (en) 1987-12-10 1988-01-27 Bradwell A R Tumour-locating agents & method of locating tumours
CA2065874C (en) 1989-09-15 2001-12-11 Joseph P. Brown Hybridoma ct43 producing a monoclonal antibody to a mucin epitope of colorectal cancer
US5165922A (en) 1990-05-22 1992-11-24 Bristol-Myers Squibb Company Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
DE4133791A1 (de) 1991-10-11 1993-04-15 Behringwerke Ag Monoklonale antikoerper gegen tumorassoziierte antigene, verfahren zu ihrer herstellung und ihre verwendung
EP0652014A1 (de) 1993-11-10 1995-05-10 National Institute Of Immunology Behandlung von Prostatahypertrophie
US5773292A (en) 1995-06-05 1998-06-30 Cornell University Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood
US6143509A (en) 1996-02-06 2000-11-07 Abbott Laboratories Prostate specific antigen peptides and uses thereof
GB9606228D0 (en) 1996-03-25 1996-05-29 Secr Defence Apparatus for matrix coating fibres with metal vapour
WO1998010292A1 (en) 1996-09-06 1998-03-12 Centocor, Inc. Monoclonal antibodies specific for prostate specific antigen and methods of detecting prostate specific antigen
IL139700A (en) * 1998-06-15 2005-09-25 Altarex Medical Corp Immunotherapeutic composition for the treatment of prostate cancer

Also Published As

Publication number Publication date
AU4159499A (en) 2000-01-05
US6881405B2 (en) 2005-04-19
US7579445B2 (en) 2009-08-25
JP2002518347A (ja) 2002-06-25
US20090220493A1 (en) 2009-09-03
ATE480566T1 (de) 2010-09-15
CA2328504A1 (en) 1999-12-23
EP1085905A1 (de) 2001-03-28
AU768002B2 (en) 2003-11-27
US20020136715A1 (en) 2002-09-26
WO1999065523A1 (en) 1999-12-23
IL139700A0 (en) 2002-02-10
EP1085905B1 (de) 2010-09-08
DE69942742D1 (de) 2010-10-21
US20050202018A1 (en) 2005-09-15

Similar Documents

Publication Publication Date Title
IL139700A (en) Immunotherapeutic composition for the treatment of prostate cancer
GB2368796A (en) Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
PT1187632E (pt) Tratamento com anticorpos anti-erbb2
NZ337413A (en) Antibodies that bind to Prostate Stem Cell Antigen (PSCA) to treat prostate cancer.
WO2004032857A8 (en) Antibody therapy
GR3036229T3 (en) Method for the production of antihuman antigen receptors and uses thereof
FR12C0004I1 (de)
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
PL331091A1 (en) Therapeutic multispecific compounds encompassing antibodies against the fcalpha receptor
PT1157041E (pt) Anticorpos para terapia e diagnostico de cancro
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
BR0309254A (pt) Uso de um anticorpo anti-ctla-4
MXPA03000527A (es) Composiciones y metodos para la terapia y diagnostico de cancer ovarico.
PL328858A1 (en) Immunogenous peptides
DE60018761D1 (de) Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
IL126803A (en) Method and composition for reconforming multiepitopic antigens to initiate an immune response
EP1411962A4 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
NZ501990A (en) Compositions containing antigen-binding fragments that recognise the antigen recognised by a recombinant 4B5 antibody
WO2002072008A3 (en) Method for treating cancer using a33 specific antibodies and chemotherapeutic agents
EP0821060A3 (de) E-Cadherin-Mutationen als Grundlage zur Diagnostik und Therapie humaner maligner Tumoren
AU3556901A (en) Use of anti-ferritin monoclonal antibodies in the treatment of some cancers
IL138021A0 (en) High affinity humanized anti-tag-72 monoclonal antibodies
NZ508119A (en) Humanized antibodies that bind specifically to verotoxin II (VT2) and/or VT2 variant and the B subunits thereof
GB9715177D0 (en) Medicament

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees